Evaluation of the predictive and prognostic potential of blood immune cell profiles in metastatic cancer patients treated with immune checkpoint inhibitors
Veera Nurmela, Anna-Mari Schroderus, Satu Tiainen, Outi Kuittinen, Olli Tenhunen, Anna Jokimäki, Sanna Suoranta, Sanna Pasonen-Seppänen, Tero Sievänen, Tuure Kinnunen, Aino Rönkä · 2026
Read Evaluation of the predictive and prognostic potential of blood immune cell profiles in metastatic cancer patients treated with immune checkpoint inhibitors by Veera Nurmela, Anna-Mari Schroderus, Satu Tiainen, Outi Kuittinen, Olli Tenhunen, Anna Jokimäki, Sanna Suoranta, Sanna Pasonen-Seppänen, Tero Sievänen, Tuure Kinnunen, Aino Rönkä (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13135614.txt.
Description
Veera Nurmela and co-authors read blood immune profiles in metastatic cancer care in a 2026 paper. Checkpoint inhibitor drugs help only a minority of patients, and blood tests that predict benefit would be cheap and easy. A back-looking cohort of 202 treated patients gives routine cell counts. A fresh cohort of forty-five gets deep flow cytometry sorting of immune subsets before and during therapy.
High monocytes and low lymphocytes before treatment track with shorter survival, they find. A mid-type monocyte subset marks poorer outcomes in the deep data. Certain memory T cell traits mark better response instead. Therapy itself raises some checkpoint marked T cells in all patients.
Catalog record
| CREATOR | Veera Nurmela, Anna-Mari Schroderus, Satu Tiainen, Outi Kuittinen, Olli Tenhunen, Anna Jokimäki, Sanna Suoranta, Sanna Pasonen-Seppänen, Tero Sievänen, Tuure Kinnunen, Aino Rönkä |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |